Consumption of Sylimarin, Pyrroloquinoline Quinone Sodium Salt and Myricetin: Effects on Alcohol Levels and Markers of Oxidative Stress—A Pilot Study
Nutrients · 2024
DOI: 10.3390/nu16172965 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Gerardo Bosco und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Padua, 35122 Padua, Italy. Hauptthemen laut MEDLINE: Oxidative Stress, Biomarkers, Flavonoids. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hyperbaric Med School of the Department of Biomedical Sciences at the University of Padova, Institute of Clinical Physiology (Milan)—National Research Council (IFC-CNR).
Abstract (Originalsprache)
Background
Alcohol abuse is one of the most common causes of mortality worldwide. This study aimed to investigate the efficacy of a treatment in reducing circulating ethanol and oxidative stress biomarkers.
Methods
Twenty wine-drinking subjects were investigated in a randomized controlled, single-blind trial (ClinicalTrials.gov. Identifier: NCT06548503; Ethical Committee of the University of Padova (HEC-DSB/12-2023) to evaluate the effect of the intake of a product containing silymarin, pyrroloquinoline quinone sodium salt, and myricetin (referred to as Si.Pi.Mi. for this project) on blood alcohol, ethyl glucuronide (EtG: marker for alcohol consumption) and markers of oxidative stress levels (Reactive Oxygen Species—ROS, Total Antioxidant Capacity—TAC, CoQ10, thiols redox status, 8-isoprostane, NO metabolites, neopterin, and uric acid). The effects of the treatment versus placebo were evaluated acutely and after 1 week of supplementation in blood and/or saliva and urine samples.
Results
Si.Pi.Mi intake reduced circulating ethanol after 120 min (−33%). Changes in oxidative stress biomarkers, particularly a TAC (range +9–12%) increase and an 8-isoprostane (marker of lipidic peroxidation) decrease (range −22–27%), were observed too.
Conclusion
After the administration of Si.Pi.Mi, the data seemed to suggest a better alcohol metabolism and oxidative balance in response to wine intake. Further verification is requested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, University of Padua, 35122 Padua, Italy.
- Institute of Clinical Physiology, National Research Council (CNR), 20159 Milan, Italy.
- Pharmatoxicology Laboratory-Hospital "Santo Spirito", 65100 Pescara, Italy.
ORCID-Profile: Gerardo Bosco, Alessandra Vezzoli, Matteo Paganini, Tommaso Antonio Giacon, Fabio Savini, Michela Montorsi, Simona Mrakic-Sposta
Förderung
- Hyperbaric Med School of the Department of Biomedical Sciences at the University of Padova
- Institute of Clinical Physiology (Milan)—National Research Council (IFC-CNR)
Zitieren
APA
Bosco, G., Vezzoli, A., Brizzolari, A., Paganini, M., Giacon, T. A., Savini, F., Gussoni, M., Montorsi, M., Dellanoce, C., & Mrakic-Sposta, S. (2024). Consumption of Sylimarin, Pyrroloquinoline Quinone Sodium Salt and Myricetin: Effects on Alcohol Levels and Markers of Oxidative Stress—A Pilot Study. Nutrients. https://doi.org/10.3390/nu16172965
Vancouver
Bosco G, Vezzoli A, Brizzolari A, Paganini M, Giacon TA, Savini F, et al. Consumption of Sylimarin, Pyrroloquinoline Quinone Sodium Salt and Myricetin: Effects on Alcohol Levels and Markers of Oxidative Stress—A Pilot Study. Nutrients. 2024. doi:10.3390/nu16172965
BibTeX
@article{Bosco2024,
author = {Bosco, Gerardo and Vezzoli, Alessandra and Brizzolari, Andrea and Paganini, Matteo and Giacon, Tommaso Antonio and Savini, Fabio and Gussoni, Maristella and Montorsi, Michela and Dellanoce, Cinzia and Mrakic-Sposta, Simona},
title = {Consumption of Sylimarin, Pyrroloquinoline Quinone Sodium Salt and Myricetin: Effects on Alcohol Levels and Markers of Oxidative Stress—A Pilot Study},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16172965}
}
EUVIMED